Contributors |
|
xi | |
Preface |
|
xv | |
|
Chapter 1 Introduction to cancer and treatment approaches |
|
|
1 | (28) |
|
Madihalli Somashekharaiah Chandraprasad |
|
|
|
|
|
1 | (2) |
|
1.2 About cancer biology: Causes and risk factors |
|
|
3 | (3) |
|
1.3 Cancer types, classification, and grading |
|
|
6 | (1) |
|
1.4 Therapeutic interventions for cancer |
|
|
7 | (12) |
|
1.5 Advanced approaches for cancer treatment |
|
|
19 | (3) |
|
|
22 | (7) |
|
|
23 | (6) |
|
Chapter 2 Taxol: Occurrence, chemistry, and understanding its molecular mechanisms |
|
|
29 | (18) |
|
|
Bala Murali Krishna Vasamsetti |
|
|
|
29 | (2) |
|
2.2 About taxol and its discovery |
|
|
31 | (2) |
|
2.3 Natural resources of taxol |
|
|
33 | (1) |
|
|
34 | (1) |
|
2.5 Mechanisms of action of taxol |
|
|
35 | (5) |
|
2.6 Conclusion and future prospects |
|
|
40 | (7) |
|
|
41 | (6) |
|
Chapter 3 Taxol: Mechanisms of actiorr against cancer, an update with current research |
|
|
47 | (26) |
|
|
|
|
3.1 The discovery and evolution of Paclitaxel (Taxol) |
|
|
47 | (1) |
|
3.2 Paclitaxel (Taxol) induces mitotic cell cycle arrest |
|
|
48 | (2) |
|
3.3 Taxol induces gene-directed apoptosis |
|
|
50 | (3) |
|
3.4 Taxol and calcium-dependent apoptosis |
|
|
53 | (4) |
|
3.5 Immunomodulation effects by Taxol |
|
|
57 | (5) |
|
3.6 Resistance mechanisms ofTaxol |
|
|
62 | (1) |
|
|
63 | (10) |
|
|
65 | (1) |
|
|
66 | (7) |
|
Chapter 4 Application of nanocarriers for paclitaxel delivery and chemotherapy of cancer |
|
|
73 | (56) |
|
|
|
|
|
|
|
|
|
|
|
|
73 | (2) |
|
|
75 | (8) |
|
|
83 | (8) |
|
|
91 | (1) |
|
|
92 | (1) |
|
|
93 | (1) |
|
|
94 | (1) |
|
|
94 | (1) |
|
|
95 | (1) |
|
|
95 | (1) |
|
|
96 | (1) |
|
|
96 | (9) |
|
4.13 Overcoming paclitaxel resistance by using Nanocarriers |
|
|
105 | (5) |
|
4.14 Selected patents for paclitaxel formulations |
|
|
110 | (4) |
|
|
114 | (15) |
|
|
114 | (15) |
|
Chapter 5 Strategies for enhancing paclitaxel bioavailability for cancer treatment |
|
|
129 | (26) |
|
|
|
|
129 | (1) |
|
5.2 Alternative paclitaxel sources |
|
|
130 | (4) |
|
5.3 Strategies of paclitaxel biosynthesis improvement in plant cell culture |
|
|
134 | (10) |
|
5.4 Mathematical modeling for paclitaxel biosynthesis optimization |
|
|
144 | (2) |
|
5.5 Concluding remarks and future perspectives |
|
|
146 | (9) |
|
|
147 | (8) |
|
Chapter 6 Botany of paclitaxel producing plants |
|
|
155 | (16) |
|
|
|
|
155 | (1) |
|
|
156 | (4) |
|
6.3 Enumeration of taxol producing plant species |
|
|
160 | (7) |
|
6.4 Taxol from angiosperms |
|
|
167 | (1) |
|
6.5 Conclusions and future direction |
|
|
168 | (3) |
|
|
168 | (3) |
|
Chapter 7 Propagation of paclitaxel biosynthesizing plants |
|
|
171 | (32) |
|
|
|
|
|
171 | (1) |
|
|
172 | (6) |
|
|
178 | (19) |
|
|
197 | (6) |
|
|
198 | (5) |
|
Chapter 8 Endophytes for the production of anticancer drug, paclitaxel |
|
|
203 | (26) |
|
|
|
|
|
|
|
|
203 | (1) |
|
8.2 Paclitaxel sources in nature |
|
|
204 | (1) |
|
8.3 Available approaches for paclitaxel production |
|
|
205 | (2) |
|
8.4 Endophytes producing paclitaxel from different host plant species |
|
|
207 | (9) |
|
8.5 Anticancer properties of endophytes-derived paclitaxel |
|
|
216 | (4) |
|
|
220 | (9) |
|
|
221 | (8) |
|
Chapter 9 Metabolic engineering strategies to enhance the production of anticancer drug, paclitaxel |
|
|
229 | (22) |
|
|
|
|
|
|
|
|
|
|
Malli Subramanian Dhanarajan |
|
|
|
|
229 | (2) |
|
9.2 Historical perspective of paclitaxel |
|
|
231 | (3) |
|
9.3 Metabolic engineering strategies for paclitaxel production |
|
|
234 | (12) |
|
|
246 | (5) |
|
|
246 | (5) |
|
Chapter 10 Paclitaxel and chemoresistance |
|
|
251 | (18) |
|
|
|
|
|
|
|
251 | (1) |
|
10.2 Mechanisms of chemoresistance |
|
|
252 | (4) |
|
10.3 Clinical markers of paclitaxel resistance |
|
|
256 | (2) |
|
10.4 Strategies to overcome paclitaxel resistance |
|
|
258 | (2) |
|
|
260 | (9) |
|
|
260 | (9) |
|
Chapter 11 Paclitaxel and cancer treatment: Non-mitotic mechanisms of paclitaxel action in cancer therapy |
|
|
269 | (18) |
|
|
|
|
|
269 | (1) |
|
11.2 Microtubule stabilization and anti-mitotic mechanisms |
|
|
270 | (1) |
|
|
271 | (1) |
|
11.4 Non-mitotic mechanisms |
|
|
272 | (1) |
|
11.5 Importance of micronucleation |
|
|
273 | (1) |
|
11.6 Innate immunity leading to the bystander effect |
|
|
274 | (1) |
|
11.7 Cellular retention of paclitaxel |
|
|
275 | (2) |
|
|
277 | (2) |
|
11.9 Prospective: New formulation of paclitaxel and additional microtubule stabilizing drugs |
|
|
279 | (1) |
|
|
280 | (7) |
|
|
280 | (7) |
|
Chapter 12 An update on paclitaxel treatment in breast cancer |
|
|
287 | (22) |
|
|
|
|
|
|
|
|
|
|
287 | (1) |
|
12.2 Types of breast cancer |
|
|
288 | (5) |
|
12.3 Molecular mechanism of paclitaxel in breast cancer |
|
|
293 | (1) |
|
12.4 Paclitaxel treatment in different types of breast cancer |
|
|
294 | (4) |
|
12.5 Adverse events and resistance due to paclitaxel treatment |
|
|
298 | (2) |
|
12.6 Efficiency of other anti-cancer drugs over paclitaxel |
|
|
300 | (1) |
|
|
300 | (9) |
|
|
301 | (1) |
|
|
301 | (8) |
|
Chapter 13 Paclitaxel conjugated magnetic carbon nanotubes induce apoptosis in breast cancer cells and breast cancer stem cells in vitro |
|
|
309 | (24) |
|
|
|
|
|
|
309 | (4) |
|
13.2 Experimental details |
|
|
313 | (3) |
|
13.3 Results and discussion |
|
|
316 | (11) |
|
|
327 | (6) |
|
|
327 | (1) |
|
Conflict of interest statement |
|
|
327 | (1) |
|
|
328 | (5) |
Index |
|
333 | |